AstraZeneca Pharmaceuticals, One MedImmune Way, Gaithersburg, MD 20878, USA.
Analysis Group, 333 South Hope Street, 27th Floor, Los Angeles, CA 90071, USA.
J Comp Eff Res. 2023 Nov;12(11):e230107. doi: 10.57264/cer-2023-0107. Epub 2023 Sep 1.
To quantify the economic burden of early-stage non-small-cell lung cancer (NSCLC) among patients with and without adjuvant therapy. All-cause and NSCLC-related healthcare resource utilization and medical costs were assessed among patients with resected stage IB-IIIA NSCLC in the SEER-Medicare database (1 January 2011-31 December 2019), from NSCLC diagnosis to death, end of continuous enrollment, or end of data availability (whichever occurred first). Patients receiving adjuvant therapy had the lowest mean NSCLC-related medical costs (adjuvant [n = 1776]: $3738; neoadjuvant [n = 56]: $5793; both [n = 47]: $4818; surgery alone [n = 3478]: $4892, per-person-per-month), driven by lower NSCLC-related hospitalization rates. Post-surgical management of early-stage NSCLC was associated with high economic burden. Adjuvant therapy was associated with numerically lower medical costs over surgical resection alone.
量化辅助治疗前后早期非小细胞肺癌（NSCLC）患者的经济负担。从 NSCLC 诊断到死亡、连续注册结束或数据可用结束（以先发生者为准），在 SEER-Medicare 数据库中评估了接受手术治疗的 IB-IIIA 期 NSCLC 患者（2011 年 1 月 1 日-2019 年 12 月 31 日）的全因和 NSCLC 相关医疗资源利用和医疗费用。接受辅助治疗的患者的 NSCLC 相关医疗费用最低（辅助治疗[n=1776]：3738 美元；新辅助治疗[n=56]：5793 美元；辅助和新辅助治疗[n=47]：4818 美元；单纯手术治疗[n=3478]：4892 美元，人均每月），这是由于 NSCLC 相关住院率较低所致。早期 NSCLC 的术后管理与高昂的经济负担相关。辅助治疗与单纯手术切除相比，医疗费用数值上较低。
